Publication:
Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program

Simple item page
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorsKorten, Volkan; Ulusoy, Sercan; Zarakolu, Pinar; Mete, Birgul
dc.date.accessioned2022-03-12T17:33:17Z
dc.date.available2022-03-12T17:33:17Z
dc.date.issued2007
dc.description.abstractThe Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/ tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. (c) 2007 Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.diagmicrobio.2007.06.016
dc.identifier.issn0732-8893
dc.identifier.pubmed17888609
dc.identifier.urihttps://hdl.handle.net/11424/228813
dc.identifier.wosWOS:000251809600016
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofDIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectantibiotic resistance surveillance
dc.subjectextended-spectrum beta-lactamases
dc.subjectmultidrug-resistant Acinetobacter
dc.subjectTEST INFORMATION COLLECTION
dc.subjectANTIMICROBIAL RESISTANCE
dc.subjectOPTAMA-PROGRAM
dc.subjectMEROPENEM
dc.subjectSPECTRUM
dc.subjectEUROPE
dc.subjectPATHOGENS
dc.subjectSUSCEPTIBILITIES
dc.subjectCOUNTRIES
dc.subjectENZYMES
dc.titleAntibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program
dc.typearticle
dspace.entity.typePublication
local.avesis.id068fcec4-1364-471e-a837-40c64261ec8f
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
oaire.citation.endPage457
oaire.citation.issue4
oaire.citation.startPage453
oaire.citation.titleDIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
oaire.citation.volume59
relation.isAuthorOfPublication27f6afa3-0e46-45c9-a302-a6493c69bffb
relation.isAuthorOfPublication.latestForDiscovery27f6afa3-0e46-45c9-a302-a6493c69bffb

Files

Collections

Research Outputs